Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
4.830
+0.260 (5.69%)
At close: Aug 13, 2025, 4:00 PM
4.720
-0.110 (-2.28%)
Pre-market: Aug 14, 2025, 9:05 AM EDT
Personalis Employees
As of December 31, 2024, Personalis had 229 total employees, including 228 full-time and 1 part-time employees. The number of employees increased by 4 or 1.78% compared to the previous year.
Employees
229
Change (1Y)
4
Growth (1Y)
1.78%
Revenue / Employee
$350,729
Profits / Employee
-$398,777
Market Cap
428.31M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PSNL News
- 8 days ago - Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 8 days ago - Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Personalis Reports Second Quarter 2025 Financial Results - Business Wire
- 22 days ago - Personalis to Announce Second Quarter 2025 Financial Results - Business Wire
- 26 days ago - Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients - Business Wire
- 2 months ago - Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO - Business Wire
- 2 months ago - New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse - Business Wire